David Goldstein, Actio Biosciences CEO (Credit: Columbia University)

Ac­tio locks in $55M Se­ries A raise to ad­vance rare dis­ease pipeline based on hu­man ge­net­ic plat­form

Ac­tio Bio­sciences has se­cured a Se­ries A raise worth $55 mil­lion to ad­vance its clin­i­cal pipeline in rare dis­eases, par­tic­u­lar­ly in pa­tients with ion chan­nel TR­PV4 mu­ta­tions.

The San Diego, CA-head­quar­tered com­pa­ny has three as­sets in its pipeline, led by its un­named pre­clin­i­cal small mol­e­cule pro­gram un­der in­ves­ti­ga­tion for Char­cot-Marie-Tooth dis­ease type 2C (CMT2C) and oth­er rare bone dis­eases. CMT2C is caused by mu­ta­tions in TR­PV4.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.